Anagnostics Boosts Sales Force
News Feb 05, 2013
Karl Winkler (48) is another sales professional checking in at Anagnostics Bioanalysis GmbH (St. Valentin/NÖ).
Karl holds a sales diploma and worked for Heinen & Loewenstein - a medtech company - and for Messer Medical Austria.
In both positions he was responsible for the build-up of sales infrastructure and sales in Austria and abroad.
Karl Winkler worked already 20 years in sales and sales management, 11 years thereof in the medical field.
Karl’s field of excellence is drugs of abuse analytics. For the beginning he will focus on sales of drugs of abuse screening tests in German speaking countries (Germany, Austria, Switzerland).
Karl Winkler: “Anagnostics is a dynamic enterprise, which is now in the phase of market expansion. Our proprietary hybcell technology promises huge market potential and I am eager to contribute to the success of the company.”
Anagnostics Bioanalysis offers its innovative multiplexed diagnostics technology named hybcell technology in three areas: drugs of abuse screening for drug therapy, in the field of personalized medicine (companion diagnostics) and for integrated sepsis diagnostics.
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018